{"id":519756,"date":"2021-07-29T07:33:32","date_gmt":"2021-07-29T11:33:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\/"},"modified":"2021-07-29T07:33:32","modified_gmt":"2021-07-29T11:33:32","slug":"intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\/","title":{"rendered":"Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., July  29, 2021  (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR\/Cas9 technology both <em>in vivo<\/em> and <em>ex vivo<\/em>, will present its second quarter 2021 financial results and operational highlights in a conference call on August 5, 2021 at 8 a.m. E.T.<\/p>\n<p>To join the call:<\/p>\n<ul type=\"disc\">\n<li>U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.<\/li>\n<li>Please visit this <a href=\"https:\/\/services.choruscall.com\/mediaframe\/webcast.html?webcastid=1WAksMxm\" rel=\"nofollow noopener\" target=\"_blank\">link<\/a> for a simultaneous live webcast of the call.<\/li>\n<\/ul>\n<p>A replay of the call will be available through the Events and Presentations page of the Investors &amp; Media section on Intellia\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2U4QoMefhDyjtxxaEFOhcL-0vWdoMwLdlAdEI1eRvR22grls3cZagmbr9AlDY2c6aMvNmRYXNE6yguPqeMReBZMb5mC9W6hnp1bJ81Uj1qE=\" rel=\"nofollow noopener\" target=\"_blank\">www.intelliatx.com<\/a>, beginning on August 5, 2021 at 12 p.m. ET.<\/p>\n<p>\n        <strong>About Intellia Therapeutics<\/strong><br \/>\n        <br \/>Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics using CRISPR\/Cas9 technology. To fully realize the transformative potential of CRISPR\/Cas9, Intellia is pursuing two primary approaches. The company\u2019s <em>in vivo<\/em> programs use intravenously administered CRISPR as the therapy, in which proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia\u2019s <em>ex vivo<\/em> programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. Intellia\u2019s deep scientific, technical and clinical development experience, along with its robust intellectual property portfolio, have enabled the company to take a leadership role in harnessing the full potential of CRISPR\/Cas9 to create new classes of genetic medicine. Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4jBPd1t36xtRMYufG4r1FuTCA_9BP8sHU4WXDwJc8BsozOnehowi20h1-3a_2GjCTDHCB5KG-w3zw11LsEVYGA==\" rel=\"nofollow noopener\" target=\"_blank\">intelliatx.com<\/a>. Follow us on Twitter\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CoMXk11U-LGIsIV3B9q5evGQS7FqEUlKlAxksjKp8uqbmdAgM_mAsCRf8VdNM0xQNOromkRmWKziniHVOfaI6Hh6ClTRjPP18LRCsgW3Avg=\" rel=\"nofollow noopener\" target=\"_blank\">@intelliatweets<\/a>.<\/p>\n<p>\n        <strong><br \/>\n          <em>Intellia Contacts:<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Ian Karp<br \/>Senior Vice President, Investor Relations and Corporate Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lo9n4ehr1ZknZ2KU4RojqH9BPurNba-Z4IIEgxt9Tw97GmvmpI3gsGdlnu0hSwGqHl5qi4HiUNOXUu4nTuaS5nzlIhVkFYy-9SG40LUsM-4=\" rel=\"nofollow noopener\" target=\"_blank\">ian.karp@intelliatx.com<\/a><\/p>\n<p>Lina Li<br \/>Director, Investor Relations<br \/>+1-857-706-1612<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5fsnyy-xvcjFm8VCAaQOgj-X4mw0pZLR1RzvEJeAKhO_Lq7U3zEM7JEdG1JkLRfLRPenUmqtNaFa8dShLFq76GnPJfZyzIHEZfHygxQ8FlU=\" rel=\"nofollow noopener\" target=\"_blank\">lina.li@intelliatx.com<\/a><\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Matt Crenson<br \/>Ten Bridge Communications<br \/>+1-917-640-7930<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iIzoiqeEizWDKmyxZkixULK0MLfkgFrT7Ym-0Ax_8T347wVkJW0oDx4iek76LmNp7yrx5KsBVc4bNfw8xQC0d5Ey5_mC5mzlK4VXvOktslU=\" rel=\"nofollow noopener\" target=\"_blank\">media@intelliatx.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Rk85cZgajwrk0mZU5WC6jXfUcbIg70hsOc1ayRmmaQ9U0rgXM48uRHmUxPO17D_HYiNGMDAMtdpC-RUMc011Cdf0TWGwTJjGZBSrmNbjx2iK5_cebHeQvmGmuot7jl9WIsL7mCGvpDkB1ROVW4vHPA==\" rel=\"nofollow noopener\" target=\"_blank\">mcrenson@tenbridgecommunications.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODQ2NCM0MzE5NTY3IzIwMjkyMDE=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/6ab01ef3-4252-45da-9e57-04f95d6ed29d\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR\/Cas9 technology both in vivo and ex vivo, will present its second quarter 2021 financial results and operational highlights in a conference call on August 5, 2021 at 8 a.m. E.T. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call. Please visit this link for a simultaneous live webcast of the call. A replay of the call will be available through the Events and Presentations page of the Investors &amp; Media &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-519756","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR\/Cas9 technology both in vivo and ex vivo, will present its second quarter 2021 financial results and operational highlights in a conference call on August 5, 2021 at 8 a.m. E.T. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call. Please visit this link for a simultaneous live webcast of the call. A replay of the call will be available through the Events and Presentations page of the Investors &amp; Media &hellip; Continue reading &quot;Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-29T11:33:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODQ2NCM0MzE5NTY3IzIwMjkyMDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates\",\"datePublished\":\"2021-07-29T11:33:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\\\/\"},\"wordCount\":332,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODQ2NCM0MzE5NTY3IzIwMjkyMDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\\\/\",\"name\":\"Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODQ2NCM0MzE5NTY3IzIwMjkyMDE=\",\"datePublished\":\"2021-07-29T11:33:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODQ2NCM0MzE5NTY3IzIwMjkyMDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4ODQ2NCM0MzE5NTY3IzIwMjkyMDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\/","og_locale":"en_US","og_type":"article","og_title":"Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates - Market Newsdesk","og_description":"CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR\/Cas9 technology both in vivo and ex vivo, will present its second quarter 2021 financial results and operational highlights in a conference call on August 5, 2021 at 8 a.m. E.T. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call. Please visit this link for a simultaneous live webcast of the call. A replay of the call will be available through the Events and Presentations page of the Investors &amp; Media &hellip; Continue reading \"Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-29T11:33:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODQ2NCM0MzE5NTY3IzIwMjkyMDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates","datePublished":"2021-07-29T11:33:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\/"},"wordCount":332,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODQ2NCM0MzE5NTY3IzIwMjkyMDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\/","name":"Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODQ2NCM0MzE5NTY3IzIwMjkyMDE=","datePublished":"2021-07-29T11:33:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODQ2NCM0MzE5NTY3IzIwMjkyMDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4ODQ2NCM0MzE5NTY3IzIwMjkyMDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-hold-conference-call-to-discuss-second-quarter-2021-earnings-and-company-updates\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/519756","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=519756"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/519756\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=519756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=519756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=519756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}